

ABOUT AMARIN®

Amarin Corporation plc (Nasdaq: AMRN) is a science-driven, biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin's lead product, VASCEPA®, is a proprietary single molecule, prescription drug consisting of icosapent ethyl. VASCEPA has been studied in two successful Phase 3 clinical studies and is in late stages of evaluation in additional ground-breaking studies, including a large late-stage cardiovascular (CV) outcomes study. Amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids.

VASCEPA is currently approved in the U.S. for the important, niche indication of lowering triglycerides in adult patients with very high triglyceride levels as an adjunct to diet.¹ Amarin markets VASCEPA in the U.S. and has begun licensing VASCEPA for international development and commercialization in China, the Middle East and Canada. In the U.S., with a focused specialty sales force in select geographies, VASCEPA, which launched in 2013, has already been prescribed over 4 million times.

Amarin commenced the landmark VASCEPA cardiovascular outcomes study, REDUCE-IT™, in 2011.² REDUCE-IT, is a global outcomes study investigating cardioprotective effects of 4 grams daily VASCEPA. In REDUCE-IT, VASCEPA is being studied as an add-on to existing statin therapy to evaluate its effect in further reducing the risk of CV events in patients with bad (LDL) cholesterol between 41-100 mg/dL who have other CV risk factors, including elevated triglyceride levels between 150 and 499 mg/dL and diabetes or experienced a previous CV event. Statin therapy, primarily focused on controlling bad (LDL) cholesterol levels, lowers cardiovascular risk by 25%-35%.³ VASCEPA targets the residual CV risk. REDUCE-IT is studying more than 8,000 patients in 11 countries with an aggregate cost of approximately \$300 million. REDUCE-IT is an event-driven cardiovascular outcomes study, not a triglyceride-lowering study. Results from this first-of-its-kind study are anticipated to become available before the end of September 2018.

Amarin is headquartered in Dublin, Ireland. In the U.S., the company's primary office is in Bedminster, N.J. For more information about VASCEPA visit www.VASCEPA.com. For more information about Amarin visit www.amarincorp.com.

ABOUT VASCEPA (ICOSAPENT ETHYL) CAPSULES INDICATION & IMPORTANT SAFETY INFORMATION

WHAT IS VASCEPA?

VASCEPA is a prescription medicine used along with a low-fat and low-cholesterol diet to lower high levels of triglycerides (fats) in adults.

- It is not known if VASCEPA changes your risk of having inflammation of your pancreas (pancreatitis).
- It is not known if VASCEPA prevents you from having a heart attack or stroke.
- It is not known if VASCEPA is safe and effective in children.

For more information about VASCEPA, visit www.vascepa.com.

Please see second page for Vascepa's important safety and other prescribing information.

IMPORTANT SAFETY INFORMATION

WHO SHOULD NOT TAKE VASCEPA?

- Do not take VASCEPA if you are allergic to icosapent ethyl or any of the ingredients in VASCEPA.

WHAT ARE THE POSSIBLE SIDE EFFECTS OF VASCEPA?

- It is not known if people who are allergic to fish or shellfish are also allergic to VASCEPA.
- If you have liver problems and are taking VASCEPA, your doctor should do blood tests during treatment.
- The most common side effect of VASCEPA is joint pain. Talk to your doctor for medical advice about side effects.

As with all drugs, you may experience a serious side effect when taking VASCEPA.

You may report side effects by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.

Tell your doctor if you take medicines that affect your blood clotting (anticoagulants or blood thinners).

Take VASCEPA capsules whole. Do not break, crush, dissolve, or chew VASCEPA capsules before swallowing.

For more information on VASCEPA, click here to see the full Patient Information or call 1-855-VASCEPA (1-855-827-2372).

Sources:

1. VASCEPA [package insert]. Bedminster, NJ: Amarin Pharma, Inc.; 2017
2. Bhatt DL, Steg PG, Brinton EA, et al. Rational and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. Clin. Cardiol. 2017;40:138-148
3. Ganda OP, Bhatt DL, Mason RP, Miller M, Boden WE. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management. J Am Coll Cardiol. 2018 (epub ahead of print). <http://www.onlinejacc.org/content/early/2018/06/13/j.jacc.2018.04.061>

Confidential: for use in media briefings only; not for detailing or distribution to non-consultant HCPs, sales professionals or patients.

Trademarks are owned by their respective companies; VASCEPA, Amarin, and VASCEPA/Amarin logos are registered trademarks of the Amarin group of companies.

©2018 Amarin Pharma, Inc. Bedminster, NJ, USA. All rights reserved.

VAS-01101 08/2018